33,314 Shares in National Research Corporation (NASDAQ:NRC) Acquired by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV bought a new position in shares of National Research Corporation (NASDAQ:NRC - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 33,314 shares of the company's stock, valued at approximately $426,000. Azzad Asset Management Inc. ADV owned approximately 0.15% of National Research as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in National Research by 88.5% during the fourth quarter. Bank of New York Mellon Corp now owns 217,212 shares of the company's stock worth $3,832,000 after acquiring an additional 101,957 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of National Research by 159.4% in the 4th quarter. JPMorgan Chase & Co. now owns 44,602 shares of the company's stock worth $787,000 after purchasing an additional 27,408 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of National Research by 6.6% during the 4th quarter. Renaissance Technologies LLC now owns 404,886 shares of the company's stock worth $7,142,000 after purchasing an additional 25,002 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in National Research by 92.9% during the 4th quarter. Ameriprise Financial Inc. now owns 34,552 shares of the company's stock valued at $610,000 after purchasing an additional 16,643 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in National Research in the fourth quarter valued at about $283,000. 47.26% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, major shareholder Patrick E. Beans bought 2,500 shares of the company's stock in a transaction dated Monday, May 12th. The stock was bought at an average price of $13.59 per share, for a total transaction of $33,975.00. Following the completion of the transaction, the insider now directly owns 35,003 shares in the company, valued at $475,690.77. The trade was a 7.69% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.10% of the stock is owned by corporate insiders.

National Research Price Performance

National Research stock traded up $0.06 during trading hours on Thursday, hitting $16.83. 109,030 shares of the stock were exchanged, compared to its average volume of 96,006. The stock has a market capitalization of $383.39 million, a P/E ratio of 16.34 and a beta of 0.38. The business's 50-day moving average is $13.17 and its two-hundred day moving average is $15.20. The company has a debt-to-equity ratio of 1.98, a quick ratio of 0.54 and a current ratio of 0.54. National Research Corporation has a 12 month low of $9.76 and a 12 month high of $27.07.

National Research (NASDAQ:NRC - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $33.55 million during the quarter. National Research had a return on equity of 71.33% and a net margin of 17.14%.

National Research Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Investors of record on Friday, June 27th will be issued a $0.12 dividend. The ex-dividend date is Friday, June 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.85%. National Research's dividend payout ratio is 46.60%.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.